Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals

Clicks: 2
ID: 314825
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #294 of 316 articles by views in european heart journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND AND AIMS: Current guidance recommends better low-density lipoprotein cholesterol (LDL-C) control in patients with elevated lipoprotein(a) [Lp(a)] as Lp(a) lowering therapies are unavailable. Whether risks attributable to Lp(a) are mitigated in patients with coronary artery disease (CAD) who achieve LDL-C <55 mg/dL remains unknown. METHODS: Multicentre retrospective observational study analysing 1581 Japanese patients with CAD [Lp(a)-JAPAN: jRCT1050260016]. Risk of major adverse cardiovascular events (MACE) (cardiac death + non-fatal myocardial infarction + coronary revascularization in non-culprit segments) was compared according to Lp(a) levels (<30, ≥30 and <50, and ≥50 mg/dL) and among LDL-C strata (<55 mg/dL vs ≥55 mg/dL) 8 weeks after percutaneous coronary intervention. RESULTS: During the 5.1-year observation among patients with LDL-C ≥55 mg/dL (n=1069), MACE occurred in 21.3% with risk of MACE increasing with Lp(a) levels (3.9, 7.9 and 11.0 events per 100 person-years for <30 mg/dL, ≥30 and <50 mg/dL, and ≥50 mg/dL, respectively; log-rank p<0.001). Among those with LDL-C <55 mg/dL (n=512), the proportion with MACE was lower overall (4.3%, p<0.001). However, elevated Lp(a) levels still identified those at higher risk of MACE (1.4, 4.7 and 7.5 events per 100 person-years in Lp(a) <30 mg/dL, ≥30 and <50 mg/dL, and ≥50mg/dL, respectively; p<0.001). Standardized 5-year MACE rate was over twice and five times higher in patients with Lp(a) ≥30 and <50 mg/dL (17.0%; adjusted hazard ratio [HR] 3.80, 95% confidence interval [CI] 1.78-8.11, p<0.001) and ≥50 mg/dL (33.4%; adjusted HR 6.90, 95% CI 3.53-13.46, p<0.001) compared to Lp(a) <30 mg/dL (5.0%). The receiver-operating characteristic analyses identified Lp(a) ≥28.2 mg/dL as the threshold for MACE (area under the curve 0.68, p<0.001). CONCLUSIONS: Whilst lower achieved LDL-C attenuates in part the risk from Lp(a), elevated Lp(a) levels still associate with worse cardiovascular outcomes. The Lp(a) threshold among Japanese patients with CAD at risk of recurrent events appears lower than in Caucasian populations, which merits further evaluation.
Reference Key
openalex_W7162242804 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Y K Kataoka, Kausik K Ray, Stephen J Nicholls, Aya Katasako-Yabumoto, Satoshi Kitahara, Hayato Hosoda, Kentarou Mitsui, Kota Murai, K S Sawada, Hideo Matama, Takamasa Iwai, S H Honda, Masashi Fujino, Shuichi Yoneda, K N Nakao, K T Takagi, Y A Asaumi, Teruo Noguchi
Journal european heart journal
Year 2026
DOI
10.1093/eurheartj/ehag446
URL
https://doi.org/10.1093/eurheartj/ehag446
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.